N/A N=50 Syncope Decision Aid for Emergency Care
Syncope
Primary: Number of Participants at End of Study — 20; 24 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Syncope, Vasovagal
Primary: Percentage of Participants Who Have Hypotensive Syncope or Near Syncope With SBP Less Than or Equal to 70 mmHG During Tilt Test — 32; 27; 33; 35 Participants — p=0.521
N/A N=140 Syncope Prediction Study
Vasovagal Syncope
Primary: Sensitivity of the Syncope Prediction Algorithm — 81; 2 Participants
N/A N=39 Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study
Syncope
Primary: Device Unable to Monitor Due to ECG Noise — 1.5 percentage of time worn
N/A N=581 Applicability of Syncope Guidelines in Cataluña
Brief Loss of Consciousness
Primary: Number of Patients That Adhere to the 2009 Syncope Guidelines (ESC2009) — 233 Participants
Phase 2 N=57 Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope
Vasovagal Syncope
Primary: Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia — 19; 10 Participants
N/A N=3 Cardioneuroablation for Neurocardiogenic Syncope
Neurocardiogenic Syncope · Vasovagal Syncope
Primary: Syncope Recurrence Rate
Phase 4 N=210 Clinical Trial for the Prevention of Vasovagal Syncope
Syncope, Vasovagal, Neurally-Mediated
Primary: The Primary Outcome Measure Will be the Recurrence of Syncope in Follow up Period. — 42; 54 Participants
N/A N=338 Presyncope (Syncope) Prevention Study
Syncope, Vasovagal
Primary: Number of Adolescents With Presyncope or Syncope After Vaccination in the Intervention and Usual Care Groups. — 80; 59 Participants — p=0.0249
N/A N=128 Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope
Syncope
Primary: Patients With Recurrence of Syncopal Episode — 10; 34 Participants — p=<0.001
Phase 4 N=77 ISSUE3: International Study on Syncope of Uncertain Etiology 3
Syncope
Primary: Syncope Recurrence Rate — 57; 25 percentage of participants — p=0.04
N/A N=101 Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block
Bifascicular Block · Syncope
Primary: Combined Endpoint Defined as First Occurrence Among the Following Events 1)Syncope Episode of Any Origin; 2)Presyncopal Episode With Documented Cardioinhibitory Origin…
N/A N=86 Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
Syncope
Primary: Number of Ambulatory Patch Monitor Participants Having Significant Symptomatic Arrhythmia — 9 Participants
N/A N=20 Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
Syncope · Syncope, Vasovagal
Primary: Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination — 70; 88; 105; 95 beats per minute
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale
Phase 4 N=24 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460
N/A N=96 Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation
Hypotension After Reperfusion in Liver Transplantation
Primary: Occurrence of Postreperfusion Syndrome (PRS) — 45; 39; 87 percentage of participants